Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ursolic acid nanoliposomes
- Development stage
- Unknown
- Lead developer
- Wuhan Liyuanheng Pharmaceutical Technology
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ursolic acid nanoliposomes are a liposomal formulation of the pentacyclic triterpenoid ursolic acid, developed by Wuhan Liyuanheng Pharmaceutical Technology. Ursolic acid is a natural compound found in various plants that exhibits potent anti-tumor, anti-inflammatory, and antioxidant properties. However, its clinical utility has historically been limited by poor water solubility and low bioavailability. The nanoliposomal delivery system enhances the solubility and targeted delivery of ursolic acid to tumor tissues. The drug works by inducing apoptosis in cancer cells, inhibiting cell proliferation, and suppressing angiogenesis through the modulation of various signaling pathways, including the inhibition of NF-κB and STAT3, and the activation of caspases. It has been investigated in Phase 1 clinical trials in China for several solid tumors, including liver, lung, and gastric cancers.
- Other names
- ursolic acid liposomesliposomal ursolic acidursolic acid liposome for injection
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)CASP3 (Caspase-3)NF-κBPI3K (Phosphoinositide-3-kinase regulatory subunit 6)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on ursolic acid nanoliposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ursolic acid nanoliposomes.